Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
UTEC - The University of Tokyo Edge Capital Partners, founded in 2004, is a prominent venture capital firm based in Tokyo, Japan. With over $1 billion in assets under management (AUM) across six funds, UTEC has established itself as a key player in the global startup ecosystem. The firm is affiliated with the University of Tokyo, which enhances its access to cutting-edge research and innovation. UTEC has invested in more than 150 startups, achieving significant milestones including 20 IPOs and 22 mergers and acquisitions, with notable exits such as PeptiDream and Mujin. The firm launched its latest fund, UTEC 6, in July 2025, raising approximately $326 million (JPY 47 billion), further solidifying its commitment to supporting transformative technologies. UTEC's reputation is built on its deep-tech focus and its ability to leverage professional knowledge and global networks to provide hands-on support to portfolio companies.
UTEC primarily invests in three key domains: Healthcare & Life Sciences, IT, and Physical Sciences & Engineering. The firm adopts a seed-and-lead investment strategy, making check sizes ranging from $500,000 to $20 million. UTEC is particularly interested in backing transformative science and technology startups that address significant global challenges. The firm emphasizes long-term support, engaging with founders from pre-incorporation through to exit. UTEC's investment approach is characterized by a bidirectional model, which not only supports Japanese startups in expanding globally but also facilitates the introduction of global innovations into the Japanese market. This strategic focus allows UTEC to identify and nurture high-potential companies that are poised to make a substantial impact in their respective fields.
UTEC boasts a diverse portfolio of over 165 companies worldwide, showcasing its strong commitment to deep-tech investments. Notable portfolio companies include 908 Devices, Fyusion, Agara, PeptiDream, and Mujin. The firm has achieved remarkable success with 20 IPOs and 22 M&A exits, demonstrating its ability to identify and support high-growth startups. UTEC's portfolio spans various sectors, particularly in biotech and healthcare, where it has made significant contributions to advancing innovative solutions. The firm's extensive network and collaboration with leading universities and research institutions further enhance its capacity to source impactful technologies and support its portfolio companies in achieving their growth objectives.
Dr. Hiroshi Matsumoto - Managing Partner, with extensive experience in venture capital and a background in technology commercialization. Yuki Tanaka - Principal, focusing on investments in healthcare and life sciences. Akira Saito - Partner, specializing in IT and physical sciences.
Founders interested in pitching to UTEC should prepare a detailed proposal that highlights their business model and technology. While specific submission guidelines are not provided, UTEC values well-structured pitches that clearly articulate the startup's vision and potential impact.
In January 2024, UTEC made its latest investment, continuing its active engagement in the startup ecosystem. The firm launched its UTEC 6 fund in July 2025, raising $326 million to further support innovative startups across its focus sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.